🇺🇸 FDA

Intelligence · Clinical Pipeline

HOFFMANN-LA ROCHE Pipeline

All ClinicalTrials.gov programs at HOFFMANN-LA ROCHE — phase, modality, and trial IDs.

Programs
286

Quick answer

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 5-Fluorouracil

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  2. 5-Fluoruracil

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  3. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Hoffmann-La Roche

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  4. A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (BFAST: Blood First Assay Screening Trial)

    Hoffmann-La Roche

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  5. A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 other active

    1 trial

  6. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  7. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

    Hoffmann-La Roche

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  8. A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

    Hoffmann-La Roche

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  9. A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  10. Afimkibart

    Hoffmann-La Roche

    Moderately to Severely Active Crohns Disease

    phase 3 small molecule active

    1 trial

  11. Aflibercept

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  12. Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  14. Alectinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. Aleglitazar

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    2 trials

  16. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  17. Atezolizumab

    Hoffmann-La Roche

    Urothelial Carcinoma

    phase 3 small molecule completed

    2 trials

  18. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  19. Atezolizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  20. Atezolizumab

    Hoffmann-La Roche

    Melanoma

    phase 3 small molecule completed

    1 trial

  21. Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  22. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Renal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  23. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  24. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  25. Baloxavir Marboxil

    Hoffmann-La Roche

    Influenza

    phase 3 small molecule completed

    1 trial

  26. Bendamustine

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  27. Bevacizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  28. Bevacizumab

    Hoffmann-La Roche

    B-cell Lymphoma

    phase 3 small molecule terminated

    1 trial

  29. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  30. Capecitabine

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  31. Carboplatin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  32. CellCept 500 mg film-coated tablets, CellCept 1 g/5 ml powder for oral suspension, Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 500 mg film-coated tablets

    Hoffmann-La Roche

    Childhood Idiopathic Nephrotic Syndrome

    phase 3 small molecule active

    1 trial

  33. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 small molecule terminated

    1 trial

  34. Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  35. Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  36. Crovalimab, Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  37. Crovalimab, ECULIZUMAB, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  38. Cytarabine

    Hoffmann-La Roche

    Leukemia, Myeloid, Acute

    phase 3 small molecule terminated

    1 trial

  39. ECULIZUMAB, Crovalimab, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  40. Entecavir

    Hoffmann-La Roche

    Pediatric Immuno-Tolerant Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  41. Faricimab

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  42. Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)

    Hoffmann-La Roche

    Early Breast Cancer

    phase 3 small molecule completed

    1 trial

  43. GEMCITABINE , Tecentriq, PEMETREXED , VINORELBINE , CISPLATIN , DOCETAXEL , Tecentriq 1,200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  44. Gantenerumab

    Hoffmann-La Roche

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial

  45. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  46. Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  47. Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

    Hoffmann-La Roche

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  48. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Hoffmann-La Roche

    Hemophilia A

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.